期刊
CELLULAR IMMUNOLOGY
卷 359, 期 -, 页码 -出版社
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.cellimm.2020.104254
关键词
IL-6; Myeloid-derived suppressor cells; Immunosuppression; Immunotherapy; Cancer
资金
- Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) [259332240/RTG 2099]
- Cooperation Program in Cancer Research of the DKFZ Heidelberg and Israel's Ministry of Science, Technology and Space (MOST) [CA181]
- German Federal Ministry of Education and Research (SERPENTINE project in the ERA PerMed network)
MDSC are crucial cells generated during tumor progression that suppress the anti-tumor functions of T and NK cells. IL-6 plays a key role in regulating the accumulation and activation of MDSC, as well as stimulating tumor cell proliferation and survival. This cytokine has pleiotropic effects on immune cell populations involved in tumor development and is a potential target for tumor immunotherapy to block MDSC-mediated immunosuppression in cancer patients.
Myeloid-derived suppressor cells (MDSC) are generated during tumor progression and suppress the anti-tumor functions of T and natural killer (NK) cells. Their enrichment is associated with a bad prognosis and a worse outcome of immunotherapy in cancer patients. The cytokine interleukin (IL)-6 was found to be a crucial regulator of MDSC accumulation and activation as well as a factor, stimulating tumor cell proliferation, survival, invasiveness and metastasis. Accordingly, IL-6 can serve as a negative prognostic marker in cancer. On the other hand, this cytokine is also involved in T cell activation. This review discusses the pleiotropic effects of IL-6 on immune cell populations that are critical for tumor development, such as MDSC and T cells, and summarizes the data on targeting IL-6 or IL-6 receptor (IL-6R) for tumor immunotherapy to block MDSC-mediated immunosuppression in cancer patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据